Advertisement

Critical limb ischaemia

Journal: Hämostaseologie
ISSN: 0720-9355
Topic:

Kongressausgabe 53. Jahrestagung der Gesellschaft für Thrombose- und Hämostaseforschung e. V. in Wien

Issue: 2009 (Vol. 29): Issue 1 2009 (1-124)
Pages: 102-109
Ahead of Print: ###MANUSCRIPT_aheadofprint###

Critical limb ischaemia

E. Minar
Department of Internal Medicine II (Director: Prof. Dr. Gerald Maurer), Medical University Vienna, Austria

Keywords

angiogenesis, critical limb ischaemia, prostanoids, revascularization

Summary

Critical limb ischaemia (CLI) is a manifestation of peripheral arterial disease (PAD) that describes patients with chronic ischaemic rest pain, or patients with ischaemic skin lesions, either ulcers or gangrene. The clinical diagnosis of CLI should be confirmed by haemodynamic parameters such as the ankle- or toe systolic pressure. The estimated annual incidence of CLI ranges between 500 and 1 000 new cases per 1 million, with diabetes being the most important risk factor. CLI is also a marker for mostly generalized and severe atherosclerosis, and therefore the prognosis of patients is poor concerning overall survival. The primary goals of treatment in patients with CLI are to relieve ischaemic pain, heal ulcers, prevent limb loss, improve patient function and quality of life and prolong overall survival. Any kind of revascularization should be done whenever technically possible, and therefore most patients should be referred to a vascular center. Furthermore, in patients with CLI a multidisciplinary approach is recommended to control pain, cardiovascular risk factors and other co-morbid disease. In patients with CLI not eligible for arterial revascularization, prostanoids are the only vasoactive drugs with proven efficacy. The safety and efficacy of the various forms of therapeutic angiogenesis still have to be proven before one can conclude on its role as an additional limb saving strategy.

You may also be interested in...

1.
A critical appraisal

H. Lawall (1), P. Bramlage (2), B. Amann (3)

Thromb Haemost 2010 103 4: 696-709

http://dx.doi.org/10.1160/TH09-10-0688

2.
Mathieu Provençal1, Marisol Michaud1, Édith Beaulieu1, David Ratel1, Georges-Étienne Rivard2, Denis Gingras1, Richard Béliveau1,2

Thromb Haemost 2008 99 3: 576-585

http://dx.doi.org/10.1160/TH07-10-0623

3.
Ping Ping Huang1, Xiao Feng Yang2, Shan Zhu Li1, Jin Chao Wen1, Yan Zhang1, Zhong Chao Han1

Thromb Haemost 2007 98 6: 1335-1342

http://dx.doi.org/10.1160/TH07-02-0137